These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29589987)

  • 41. First macrocyclic 3
    Basit S; Ashraf Z; Lee K; Latif M
    Eur J Med Chem; 2017 Jul; 134():348-356. PubMed ID: 28431340
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tyrosine kinase inhibitors.
    Natoli C; Perrucci B; Perrotti F; Falchi L; Iacobelli S;
    Curr Cancer Drug Targets; 2010 Aug; 10(5):462-83. PubMed ID: 20384577
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics.
    Tibes R; Trent J; Kurzrock R
    Annu Rev Pharmacol Toxicol; 2005; 45():357-84. PubMed ID: 15822181
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer.
    Shaw AT
    Clin Adv Hematol Oncol; 2015 May; 13(5):282-4. PubMed ID: 26352769
    [No Abstract]   [Full Text] [Related]  

  • 45. Emerging Biomarkers in Personalized Therapy of Lung Cancer.
    Cagle PT; Raparia K; Portier BP
    Adv Exp Med Biol; 2016; 890():25-36. PubMed ID: 26703797
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [ALK inhibitor].
    Mano H
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):27-30. PubMed ID: 21368458
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.
    Kondo T; Hashimoto Y; Kobayashi H; Iizuka J; Nishikawa T; Nakano M; Tanabe K
    Jpn J Clin Oncol; 2010 Dec; 40(12):1173-9. PubMed ID: 20696817
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
    Golding B; Luu A; Jones R; Viloria-Petit AM
    Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer.
    Stinchcombe TE
    Curr Treat Options Oncol; 2016 Apr; 17(4):18. PubMed ID: 26961971
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives.
    Haddad FG; Kourie HR; Kattan J
    Future Oncol; 2017 Feb; 13(3):201-204. PubMed ID: 27624407
    [No Abstract]   [Full Text] [Related]  

  • 51. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
    Gridelli C
    Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
    [No Abstract]   [Full Text] [Related]  

  • 52. The Revised College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline: A Step Forward for Molecular Cytopathology.
    Aisner DL
    Arch Pathol Lab Med; 2018 Jun; 142(6):684-685. PubMed ID: 29595315
    [No Abstract]   [Full Text] [Related]  

  • 53. [Kinase inhibitors in oncology : What is new?].
    Riedmann K; Bassermann F; Jost PJ
    Internist (Berl); 2019 May; 60(5):540-544. PubMed ID: 30859279
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeted anti-cancer therapy in the elderly.
    Gonsalves W; Ganti AK
    Crit Rev Oncol Hematol; 2011 Jun; 78(3):227-42. PubMed ID: 20599391
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Best Use of the Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer: Discussion.
    Tuttle RM; Brose MS
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 9):12-3. PubMed ID: 27168343
    [No Abstract]   [Full Text] [Related]  

  • 57. [Is chemotherapy still a valid option for oncogene-addicted lung cancer? Yes].
    Besse B
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S93-5. PubMed ID: 26118884
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors.
    Kanthala S; Pallerla S; Jois S
    Future Oncol; 2015; 11(5):865-78. PubMed ID: 25757687
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The anaplastic lymphoma kinase testing conundrum.
    Conde E; Taniere P; Lopez-Rios F
    Expert Rev Mol Diagn; 2015 Feb; 15(2):161-3. PubMed ID: 25579121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.